VistaGen Therapeutics, Inc.
VTGN
$2.22
-$0.12-5.13%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -47.30M | -39.57M | -33.19M | -29.36M | -32.07M |
| Total Depreciation and Amortization | 615.50K | 597.50K | 579.50K | 567.50K | 558.90K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.62M | 3.15M | 2.76M | 2.19M | 5.82M |
| Change in Net Operating Assets | 3.84M | 2.12M | 849.30K | 581.30K | -612.90K |
| Cash from Operations | -39.23M | -33.70M | -29.00M | -26.03M | -26.30M |
| Capital Expenditure | -131.70K | -163.70K | -102.70K | -60.70K | -32.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -528.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.57M | -13.15M | -5.43M | -- | -- |
| Cash from Investing | -13.70M | -13.31M | -5.53M | -60.70K | -560.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 1.00K | 2.00K | -783.00K | -984.00K | -1.30M |
| Issuance of Common Stock | 1.26M | 129.85M | 129.85M | 129.77M | 129.77M |
| Repurchase of Common Stock | -168.80K | -168.80K | -168.80K | -168.80K | -500.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -36.03M | -1.07M | 0.00 | -84.40K |
| Cash from Financing | 1.09M | 93.65M | 127.83M | 128.61M | 128.38M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -51.84M | 46.64M | 93.30M | 102.53M | 101.52M |